

AMENDMENTS TO THE CLAIMS

Please amend claim 81, as shown below. A complete listing of the claims, including their current status, is set forth below.

1-58. (Cancelled)

58. (Withdrawn) A method of screening a plurality of cells, comprising:

- a) producing a plurality of cells comprising a library of nucleic acids encoding a library of exogenous scaffolds;
- b) introducing into said plurality of cells a library of nucleic acids each encoding at least a first enzyme and a second enzyme, wherein each of said enzymes comprises an exogenous binding sequence; and
- c) screening said plurality of cells for a cell comprising at least one exogenous scaffold and exhibiting an altered phenotype,

wherein each of said scaffolds comprises at least a first binding site and a second binding site, and wherein said first enzyme binds to said first binding site and said second enzyme binds to said second binding site.

59. (Withdrawn) The method of claim 58 or 80, further comprising contacting said cells, prior to said screening, with a library of exogenous bioactive agent precursors.

60. (Withdrawn) A method according to claim 58 or 80, wherein each said scaffold comprises at least three binding sites.

61. (Withdrawn) A method according to claim 58 or 80, wherein each said scaffold comprises at least four binding sites.

62. (Withdrawn) A method according to claim 58 or 80, wherein each said scaffold comprises at least five binding sites.

63. **(Withdrawn)** A method according to claim 58 or 80, wherein said cells are mammalian cells.
64. **(Withdrawn)** A method according to claim 58 or 80, wherein said scaffolds are linear.
65. **(Withdrawn)** A method according to claim 58 or 80, wherein said library of nucleic acids encoding a library of exogenous scaffolds further comprises at least one targeting sequence.
66. **(Withdrawn)** A method according to claim 58 or 80, wherein said library of nucleic acids encoding a library of exogenous scaffolds further comprises at least one rescue sequence.
67. **(Withdrawn)** A method according to claim 58 or 80, wherein said library of nucleic acids encoding a library of exogenous scaffolds further comprises at least one stability sequence.
68. **(Withdrawn)** A method according to claim 58 or 80, wherein said library of nucleic acids encoding at least a first enzyme and a second enzyme further comprises at least one targeting sequence.
69. **(Withdrawn)** A method according to claim 58 or 80, wherein said library of nucleic acids encoding at least a first enzyme and a second enzyme further comprises at least one rescue sequence.
70. **(Withdrawn)** A method according to claim 58 or 80, wherein said library of nucleic acids encoding at least a first enzyme and a second enzyme further comprises at least one stability sequence.
71. **(Withdrawn)** A method according to claim 58 or 80, wherein said introducing comprises retroviral infection.
72. **(Withdrawn)** A method according to claim 58 or 80, wherein said method further comprises isolating said cell exhibiting an altered phenotype.
73. **(Withdrawn)** A method according to claim 58 or 80 further comprising isolating said scaffold from said cell exhibiting an altered phenotype.

74. **(Withdrawn)** A method according to claim 58 or 80 further comprising isolating said nucleic acid encoding said scaffold from said cell exhibiting an altered phenotype.

75. **(Withdrawn)** A method according to claim 58 or 80 further comprising isolating said enzymes from said cell exhibiting an altered phenotype.

76. **(Withdrawn)** A method according to claim 58 or 80 further comprising isolating said nucleic acids encoding said enzymes from said cell exhibiting an altered phenotype.

77. **(Withdrawn)** A method according to claim 59, wherein said altered phenotype is due to the presence of one or more of said bioactive agent precursors.

78. **(Withdrawn)** A method according to claim 77 further comprising identifying said one or more bioactive agents.

79. **(Withdrawn)** A method according to claim 58 or 80, wherein said nucleic acids contain localization signals.

80. **(Withdrawn)** A method of screening a plurality of cells, comprising:

- a) producing a plurality of cells comprising a library of nucleic acids encoding a library of exogenous scaffolds;
- b) introducing into said plurality of cells a library of retroviral vectors comprising nucleic acids each encoding at least a first enzyme and a second enzyme; and
- c) screening said plurality of cells for a cell comprising at least one exogenous scaffold and exhibiting an altered phenotype,
wherein each of said scaffolds comprises at least a first binding site and a second binding site, and wherein said first enzyme binds to said first binding site and said second enzyme binds to said second binding site.

81. **(Currently amended)** A method of screening for an enzymatic complex that confers an altered phenotype upon a cell, comprising:

screening a plurality of cells for an altered phenotype, wherein the plurality of cells comprise a plurality of different enzymatic complexes, each cell comprising

a nucleic acid encoding an non-naturally occurring exogenous scaffold comprising a first binding sequence and a second binding sequence; and

nucleic acids encoding first and second enzymes, each enzyme comprising an exogenous binding sequence, which exogenous binding sequence binds to one of the first and second binding sequences of the scaffold to form an enzymatic complex;

wherein the enzymatic complex confers upon the cell an altered phenotype relative to a phenotype of the cell in the absence of said complex.

82. **(Withdrawn)** The method of claim 81, wherein said screening is in the presence of a candidate bioactive agent or precursor thereof.

83. **(Previously presented)** The method of claim 81, further comprising an identifying an enzymatic complex that alters the phenotype of cell.